Serum YKL-40 and gestational diabetes - an observational cohort study

APMIS. 2016 Sep;124(9):770-5. doi: 10.1111/apm.12573. Epub 2016 Jul 25.

Abstract

To examine serum YKL-40 in women developing gestational diabetes mellitus (GDM). In the present large observational cohort study of 1179 pregnant women, we determined serum YKL-40 four times during pregnancy (at gestational age 12, 20, 25, and 32 weeks). Pregnancy outcome was obtained from medical records. Sixty-eight women (5.8%) developed GDM. Serum YKL-40 increased from gestational age (GA) 12 weeks and the following weeks in the women who developed GDM and was independent of BMI, parity, and maternal age (OR = 2.69, 95% CI: 1.45-5.00, p = 0.002). No association was found between serum YKL-40 and the oral glucose tolerance test results. In conclusion, YKL-40 significantly increased in pregnant women with GDM compared with women without GDM, probably reflecting the low-grade inflammation of GDM. However, we did not find an association between serum concentrations of YKL-40 in early pregnancy and the development of GDM and thus we conclude that YKL-40 alone is not usable as a biomarker for early prediction of GDM.

Keywords: Pregnancy; YKL-40; biomarker; gestational diabetes mellitus.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / blood*
  • Chitinase-3-Like Protein 1 / blood*
  • Cohort Studies
  • Diabetes, Gestational / diagnosis*
  • Diabetes, Gestational / pathology*
  • Female
  • Glucose Tolerance Test
  • Humans
  • Middle Aged
  • Pregnancy
  • Serum / chemistry*
  • Young Adult

Substances

  • Biomarkers
  • CHI3L1 protein, human
  • Chitinase-3-Like Protein 1